CADL – candel therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer [Yahoo! Finance]
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
Candel Therapeutics: 'Cancer Vaccine' Buy Thesis Appears Compelling [Seeking Alpha]
Candel Therapeutics (CADL) is now covered by Cantor Fitzgerald. They set an "overweight" rating on the stock.
Candel Therapeutics (CADL) was downgraded by Zacks Research from "hold" to "strong sell".
Form ARS Candel Therapeutics, For: Dec 31
Form DEFA14A Candel Therapeutics,
Form DEF 14A Candel Therapeutics, For: Jun 23
Form SCHEDULE 13G/A Candel Therapeutics, Filed by: BlackRock, Inc.
Form 4 Candel Therapeutics, For: Mar 31 Filed by: Manning Paul B
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.